Literature DB >> 21415216

Role of ERK-BIM and STAT3-survivin signaling pathways in ALK inhibitor-induced apoptosis in EML4-ALK-positive lung cancer.

Ken Takezawa1, Isamu Okamoto, Kazuto Nishio, Pasi A Jänne, Kazuhiko Nakagawa.   

Abstract

PURPOSE: EML4-ALK (echinoderm microtubule-associated protein-like 4 anaplastic lymphoma kinase) was recently identified as a transforming fusion gene in non-small cell lung cancer. The purpose of the present study was to characterize the mechanism of malignant transformation by EML4-ALK. EXPERIMENTAL
DESIGN: We established NIH 3T3 cells that stably express variant 1 or 3 of EML4-ALK and examined the signaling molecules that function downstream of EML4-ALK.
RESULTS: Forced expression of EML4-ALK induced marked activation of extracellular signal-regulated kinase (ERK) and STAT3, but not that of AKT. Inhibition of ERK or STAT3 signaling resulted in substantial attenuation of the proliferation of cells expressing either variant of EML4-ALK, suggesting that these signaling pathways function downstream of EML4-ALK in lung cancer cells. The specific ALK inhibitor TAE684 induced apoptosis that was accompanied both by upregulation of BIM, a proapoptotic member of the Bcl-2 family, and by downregulation of survivin, a member of the inhibitor of apoptosis protein (IAP) family, in EML4-ALK-expressing NIH 3T3 cells as well as in H3122 human lung cancer cells harboring endogenous EML4-ALK. Depletion of BIM and overexpression of survivin each inhibited TAE684-induced apoptosis, suggesting that both upregulation of BIM and downregulation of survivin contribute to TAE684-induced apoptosis in EML4-ALK-positive lung cancer cells. Furthermore, BIM and survivin expression was found to be independently regulated by ERK and STAT3 signaling pathways, respectively.
CONCLUSIONS: ALK inhibitor-induced apoptosis is mediated both by BIM upregulation resulting from inhibition of ERK signaling as well as by survivin downregulation resulting from inhibition of STAT3 signaling in EML4-ALK-positive lung cancer cells. ©2011 AACR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21415216     DOI: 10.1158/1078-0432.CCR-10-2798

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  59 in total

1.  BIM expression in treatment-naive cancers predicts responsiveness to kinase inhibitors.

Authors:  Anthony C Faber; Ryan B Corcoran; Hiromichi Ebi; Lecia V Sequist; Belinda A Waltman; Euiheon Chung; Joao Incio; Subba R Digumarthy; Sarah F Pollack; Youngchul Song; Alona Muzikansky; Eugene Lifshits; Sylvie Roberge; Erik J Coffman; Cyril H Benes; Henry L Gómez; José Baselga; Carlos L Arteaga; Miguel N Rivera; Dora Dias-Santagata; Rakesh K Jain; Jeffrey A Engelman
Journal:  Cancer Discov       Date:  2011-07-22       Impact factor: 39.397

2.  Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.

Authors:  Ryohei Katayama; Alice T Shaw; Tahsin M Khan; Mari Mino-Kenudson; Benjamin J Solomon; Balazs Halmos; Nicholas A Jessop; John C Wain; Alan Tien Yeo; Cyril Benes; Lisa Drew; Jamal Carlos Saeh; Katherine Crosby; Lecia V Sequist; A John Iafrate; Jeffrey A Engelman
Journal:  Sci Transl Med       Date:  2012-01-25       Impact factor: 17.956

3.  Ubiquitin-conjugating enzyme E2C regulates apoptosis-dependent tumor progression of non-small cell lung cancer via ERK pathway.

Authors:  Zhongmian Zhang; Ping Liu; Jian Wang; Tianxiao Gong; Fang Zhang; Jun Ma; Na Han
Journal:  Med Oncol       Date:  2015-04-02       Impact factor: 3.064

Review 4.  New strategies for treatment of ALK-rearranged non-small cell lung cancers.

Authors:  Takaaki Sasaki; Pasi A Jänne
Journal:  Clin Cancer Res       Date:  2011-10-18       Impact factor: 12.531

Review 5.  Apoptotic agents.

Authors:  Dean A Fennell
Journal:  Transl Lung Cancer Res       Date:  2013-06

Review 6.  Targeted inhibition in tumors with ALK dependency.

Authors:  Eunice L Kwak; Jeffrey W Clark; Alice T Shaw
Journal:  Lung Cancer (Auckl)       Date:  2013-01-09

Review 7.  The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics.

Authors:  Aaron N Hata; Jeffrey A Engelman; Anthony C Faber
Journal:  Cancer Discov       Date:  2015-04-20       Impact factor: 39.397

8.  Induction of autophagy contributes to crizotinib resistance in ALK-positive lung cancer.

Authors:  Cheng Ji; Li Zhang; Yan Cheng; Raj Patel; Hao Wu; Yi Zhang; Mian Wang; Shundong Ji; Chandra P Belani; Jin-Ming Yang; Xingcong Ren
Journal:  Cancer Biol Ther       Date:  2014-02-20       Impact factor: 4.742

Review 9.  Regulation of Bim in Health and Disease.

Authors:  Ronit Vogt Sionov; Spiros A Vlahopoulos; Zvi Granot
Journal:  Oncotarget       Date:  2015-09-15

Review 10.  Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology.

Authors:  Sai-Hong Ignatius Ou; Cynthia Huang Bartlett; Mari Mino-Kenudson; Jean Cui; A John Iafrate
Journal:  Oncologist       Date:  2012-09-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.